Search
Vaccines Treatment Options in New York, NY
A collection of 94 research studies where Vaccines is the interventional treatment. These studies are located in the New York, NY. Vaccines is used for conditions such as Influenza, COVID-19 and Hepatitis B.
1 - 12 of 94
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age
Recruiting
This study is a Phase 3, randomized, modified double-blind study which aims to document the safety profile of the PCV21 vaccine (investigational pneumococcal vaccine) compared to a licensed 20-valent pneumococcal conjugate vaccine in infants aged from approximately 2 months (42 to 89 days).
The study duration per participant will be up to approximately 19 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 to 15 months of age. Routine pediatr... Read More
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
08/21/2025
Locations: Child Health Care Associates - Site Number : 8400005, East Syracuse, New York +1 locations
Conditions: Pneumococcal Immunization
A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults
Active Not Recruiting
This purpose of this phase 3 multicenter, parallel-group, open-label study is to learn about the safety, tolerability, and immunogenicity of RSVpreF and HZ/su vaccine when given together in adults 50 years of age and older.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/13/2025
Locations: NYU Langone Health, New York, New York
Conditions: Respiratory Syncytial Virus (RSV)
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
Recruiting
This phase II trial studies how well nab-paclitaxel, durvalumab, and tremelimumab with or without personalized synthetic long peptide vaccine (neoantigen vaccine) works in treating patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/09/2025
Locations: NYP/Weill Cornell Medical Center, New York, New York
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Invasive Breast Carcinoma
Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
Active Not Recruiting
This study aims to use vaccination information from state vaccine registries linked with HealthVerity insurance claims for the following:
* to measure how effective the Pfizer-BioNTech vaccine is at preventing post-COVID conditions.
* to understand characteristics of patients who are receiving COVID-19 vaccines.
All patients whose information is kept unidentified in the HealthVerity database are eligible to be included for both aims of this study.
Gender:
ALL
Ages:
6 months and above
Trial Updated:
08/04/2025
Locations: Pfizer, New York, New York
Conditions: SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
Terminated
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications. All study participants will have negative serologic or suboptimal responses (defined as a Roche Elecsys® Anti-SARS-CoV-2 S result ≤200 U/mL) or a low immune response (defined as a Roche Elecsys® Anti-SARS-CoV-2 S result \>200 U/ml and ≤2500 U/mL) to their previous doses of COVID-19 v... Read More
Gender:
ALL
Ages:
2 years and above
Trial Updated:
08/04/2025
Locations: Feinstein Institute for Medical Research: Center for Autoimmune and Musculoskeletal Diseases, Manhasset, New York +6 locations
Conditions: Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Systemic Sclerosis (SSc), Pediatric SLE, Pediatric-Onset Multiple Sclerosis (POMS), Rheumatoid Arthritis (RA), Multiple Sclerosis (MS), Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM)
Long-Term PF-06651600 for the Treatment of Alopecia Areata
Active Not Recruiting
This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata. Eligible patients from the prior studies B7931005 (NCT02974868) and B7981015 (NCT03732807) will have an opportunity to enroll as well as patients who have not previously participated in either of these studies. The study is open-label and all patients entering the study will receive active study drug... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/28/2025
Locations: NYU School of Medicine, The Ronald O. Perelman Department of Dermatology, New York, New York +2 locations
Conditions: Alopecia Areata
COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
Completed
Background: Allergic reactions have been reported to occur after vaccination with both the Pfizer-BioNTech COVID-19 Vaccine and Moderna COVID-19 Vaccine. Allergic reactions range from mild to severe and include life- threatening anaphylactic reactions, although no deaths have been reported with either vaccine.
This study is designed with two principal aims:
* To estimate the proportions of systemic allergic reactions to the Pfizer-BioNTech COVID-19 Vaccine and the Moderna COVID-19 Vaccine in a... Read More
Gender:
ALL
Ages:
5 years and above
Trial Updated:
07/25/2025
Locations: Mount Sinai Hospital, Department of Medicine, Division of Clinical Immunology, New York, New York +2 locations
Conditions: SARS-CoV Infection, COVID-19, Allergic Reaction, Mast Cell Disorder
VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions
Completed
This phase II trial studies the use of human papillomavirus (HPV) deoxyribonucleic acid (DNA) plasmids therapeutic vaccine VGX-3100 (VGX-3100) and electroporation in treating patients with human immunodeficiency virus (HIV)-positive high-grade anal lesions. Vaccines made from DNA may help the body build an effective immune response to kill tumor cells. Electroporation helps pores in your body's cells take in the drug to strengthen your immune system's response. Giving VGX-3100 and electroporatio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Montefiore Medical Center, Bronx, New York +1 locations
Conditions: Anal Intraepithelial Neoplasia, High Grade Squamous Intraepithelial Neoplasia, HIV Positivity, Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive
Text4Vax: Text Message Reminders for Pediatric COVID-19 and Influenza Vaccines 2024-25 Season
Completed
This multi-site study assesses the impact of text message reminders on the receipt of COVID-19 and influenza text message reminders takes place primarily in practices from the American Academy of Pediatrics (AAP) Pediatric Research in Office Settings (PROS) network.
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
07/09/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Influenza, COVID-19, Vaccination Hesitancy
A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza
Active Not Recruiting
The purpose of this study is to learn about the safety and effects of the study vaccine for the possible prevention of influenza. Influenza is a disease that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. The study vaccine is called Pandemic Influenza modRNA (pdmFlu) Vaccine.
This study is seeking for participants who are:
* between the ages of 18 to 49 years old or 65 to 84 years old.
* willing and able to follow with all scheduled visits,... Read More
Gender:
ALL
Ages:
Between 18 years and 84 years
Trial Updated:
06/27/2025
Locations: NYU Langone Health, New York, New York
Conditions: Grippe, Influenza, Vaccines
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age
Completed
The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1083 as compared with active control, co-administered licensed influenza and severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) vaccines, in 2 independent age-group sub-study cohorts, healthy adults 65 years and older (Cohort A) and healthy adults 50 to \<65 years of age (Cohort B).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/23/2025
Locations: DM Clinical Research - Brooklyn, Brooklyn, New York +2 locations
Conditions: SARS-CoV-2, Influenza
Prospective Trial of Vaccine Responses in Childhood Cancer Survivors
Completed
This study will look at your body's response to the new immunizations. We want to see how well they will protect you. Immunization is the same as vaccination. Our goal is to protect you as much as we can. We do not want you to have the measles, mumps, or whooping cough. We are doing the study because there is no standard way to re-immunize people after cancer treatments.
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
06/12/2025
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Childhood Cancer, Multiple Diseases
1 - 12 of 94